Close Menu

NEW YORK (GenomeWeb) – AMRI has announced a strategic alliance with Bruker Daltonics and HighRes Biosolutions to implement new mass spectrometry technology in drug discovery.

AMRI, a contract research organization, will implement Bruker Daltonics' MALDI PharmaPulse system at its Integrated Drug Discovery Center. Under the terms of the alliance, Bruker Daltonics and HighRes will train and consult with AMRI researchers as they develop protocols for high-throughput screening in drug discovery.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.